已收盤 09-20 16:00:00 美东时间
-2.110
-1.75%
Welcome to Seeking Alpha's Catalyst Watch - a breakdown of some of next week's actionable events that stand out. Check out Seeking Alpha's earnings calendar for a full list of companies due to report....
今天 03:00
Cantor Fitzgerald analyst Charles Duncan reiterates Neurocrine Biosciences (NASDAQ:NBIX) with a Overweight and maintains $155 price target.
09-17 00:21
Unity Software(U.US) reported fourth-quarter financial results after the market...
09-17 00:20
Companies in the Healthcare sector have received a lot of coverage today as ana...
09-13 08:44
Neurocrine Biosciences (NASDAQ:NBIX) has halted development of luvadaxistat due to disappointing results from a Phase 2 study of the drug in the treatment of cognitive impairment in schizophrenia pati...
09-13 04:58
Unity Software(U.US) reported fourth-quarter financial results after the market...
09-13 04:33
Second Phase 2 Study for Luvadaxistat Fails to Meet Primary Endpoint as Potential Treatment for Cognitive Impairment Associated with SchizophreniaResults Confounded by Variability in Cognition Measures Across Population
09-13 04:11
Neurocrine Biosciences- Will Focus Efforts and Resources on Advancement Into Ph...
09-13 04:07
Neurocrine Biosciences Inc - Luvadaxistat Did Not Meet Primary Endpoint in This...
09-13 04:06
Neurocrine Biosciences Provides Update on Erudite™ Phase 2 Data for Luvadaxista...
09-13 04:05